Tags

Type your tag names separated by a space and hit enter

Real life evaluation of safinamide effectiveness in Parkinson's disease.
Neurol Sci. 2018 Apr; 39(4):733-739.NS

Abstract

In this retrospective study, we evaluated both efficacy and effectiveness of safinamide 50 and 100 mg in the treatment of motor fluctuations and disabling dyskinesias in a cohort of patients with idiopathic Parkinson's disease (PD). Ninety-one PD patients were evaluated during the first year of commercialization of the drug, both prior to starting safinamide and at the last available follow-up. Evaluations were based on the Unified Parkinson's Disease Scale part III (UPDRS III), Hoehn & Yahr (HY), Unified Dyskinesia Rating Scale (UDysRS) walking and balance item 9 score, daily time spent in OFF and in ON with disabling dyskinesias (1 week diary), mean daily dose of levodopa (LD), dopamine-agonists (DA), catechol-O-methyl transferase inhibitor (COMT-I), monoamine oxidase B inhibitor (MAOB-I), and their LD equivalent dose (LEDD). Eight patients withdrew safinamide within the first month for minor side effects. At the follow-up evaluation, after a mean time with safinamide of 7.5 months ± 3.4, all patients showed a significant improvement of all the scale scores, except for HY, and of the daily dosages of the drugs and the LEDD. The same results were shown by PD patients treated with safinamide 50 mg and patients who started safinamide without switching from a previous MAOBI. PD patients with safinamide 100 mg and patients who started safinamide switching from a previous MAOBI significantly improved in time spent in OFF and LEDD. In conclusion, safinamide is safe and effective in improving motor complications in patients with idiopathic PD and can be considered a useful levodopa sparing strategy.

Authors+Show Affiliations

Department of Neurology-Stroke Unit and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy. Francesca.mancini@tin.it.Neurology Unit, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, "Dino Ferrari" Center, Neuroscience Section, Department of Pathophysiology and Transplantation, Università Degli Studi di Milano, Milan, Italy.Neurology Unit, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, "Dino Ferrari" Center, Neuroscience Section, Department of Pathophysiology and Transplantation, Università Degli Studi di Milano, Milan, Italy.Neuropathophysiology Unit, IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy.Department of Neurology-Stroke Unit and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy. Department of Neurology-Stroke Unit and Laboratory of Neuroscience, "Dino Ferrari" Centre - Centre for Neurotechnology and Brain Therapeutics, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.Neurology Service, Casa di Cura Humanitas San Pio X, Milan, Italy.Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29441484

Citation

Mancini, Francesca, et al. "Real Life Evaluation of Safinamide Effectiveness in Parkinson's Disease." Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, vol. 39, no. 4, 2018, pp. 733-739.
Mancini F, Di Fonzo A, Lazzeri G, et al. Real life evaluation of safinamide effectiveness in Parkinson's disease. Neurol Sci. 2018;39(4):733-739.
Mancini, F., Di Fonzo, A., Lazzeri, G., Borellini, L., Silani, V., Lacerenza, M., & Comi, C. (2018). Real life evaluation of safinamide effectiveness in Parkinson's disease. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 39(4), 733-739. https://doi.org/10.1007/s10072-018-3272-y
Mancini F, et al. Real Life Evaluation of Safinamide Effectiveness in Parkinson's Disease. Neurol Sci. 2018;39(4):733-739. PubMed PMID: 29441484.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Real life evaluation of safinamide effectiveness in Parkinson's disease. AU - Mancini,Francesca, AU - Di Fonzo,Alessio, AU - Lazzeri,Giulia, AU - Borellini,Linda, AU - Silani,Vincenzo, AU - Lacerenza,Marco, AU - Comi,Cristoforo, Y1 - 2018/02/13/ PY - 2017/11/15/received PY - 2018/02/01/accepted PY - 2018/2/15/pubmed PY - 2018/9/7/medline PY - 2018/2/15/entrez KW - Dyskinesias KW - Motor fluctuations KW - Parkinson’s disease KW - Safinamide SP - 733 EP - 739 JF - Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology JO - Neurol. Sci. VL - 39 IS - 4 N2 - In this retrospective study, we evaluated both efficacy and effectiveness of safinamide 50 and 100 mg in the treatment of motor fluctuations and disabling dyskinesias in a cohort of patients with idiopathic Parkinson's disease (PD). Ninety-one PD patients were evaluated during the first year of commercialization of the drug, both prior to starting safinamide and at the last available follow-up. Evaluations were based on the Unified Parkinson's Disease Scale part III (UPDRS III), Hoehn & Yahr (HY), Unified Dyskinesia Rating Scale (UDysRS) walking and balance item 9 score, daily time spent in OFF and in ON with disabling dyskinesias (1 week diary), mean daily dose of levodopa (LD), dopamine-agonists (DA), catechol-O-methyl transferase inhibitor (COMT-I), monoamine oxidase B inhibitor (MAOB-I), and their LD equivalent dose (LEDD). Eight patients withdrew safinamide within the first month for minor side effects. At the follow-up evaluation, after a mean time with safinamide of 7.5 months ± 3.4, all patients showed a significant improvement of all the scale scores, except for HY, and of the daily dosages of the drugs and the LEDD. The same results were shown by PD patients treated with safinamide 50 mg and patients who started safinamide without switching from a previous MAOBI. PD patients with safinamide 100 mg and patients who started safinamide switching from a previous MAOBI significantly improved in time spent in OFF and LEDD. In conclusion, safinamide is safe and effective in improving motor complications in patients with idiopathic PD and can be considered a useful levodopa sparing strategy. SN - 1590-3478 UR - https://www.unboundmedicine.com/medline/citation/29441484/Real_life_evaluation_of_safinamide_effectiveness_in_Parkinson's_disease_ L2 - https://dx.doi.org/10.1007/s10072-018-3272-y DB - PRIME DP - Unbound Medicine ER -